This is a working overview of anti-doping testing, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
=== Inflammatory bowel disease === There is only a little evidence of its effectiveness in treating functional symptoms in inflammatory bowel disease from small studies that are susceptible to bias. The low-FODMAP diet is not recommended for ulcerative colitis due to risk of disruption of nutritional status and insufficient evidence of beneficial effects.
=== Organic chemistry === Some synthetic macromolecules, such as catenanes and rotaxanes, dendrimers and hyperbranched polymers, and other assemblies, have molecular weights extending into the thousands or tens of thousands, where most ionization techniques have difficulty producing molecular ions. MALDI is a simple and fast analytical method that can allow chemists to rapidly analyze the results of such syntheses and verify their results.
Krugman, Paul, "The American Way of Economic war: Is Washington Overusing Its Most Powerful Weapons?" (review of Henry Farrell and Abraham Newman, Underground Empire: How America Weaponized the World Economy, Henry Holt, 2023, 288 pp.), Foreign Affairs, vol. 103, no. 1 (January/February 2024), pp. 150–156. Mulder, Nicholas. The Economic Weapon: The Rise of Sanctions as a Tool of Modern War (2022) also see online review
== History == The term "hydrocolloid" was coined in the 1960s during the development of mucoadhesives, first used to treat mouth ulcers. The term was later adopted for a new dressing type in which a hydrophilic gelable mass was applied to a flexible semipermeable carrier. It was first sold under the brand Granuflex in the United Kingdom in 1982, and then DuoDERM in the United States in 1983. Different products subsequently came to market with slightly varying formulations, designed for specific areas of the body or specific purposes (for example, postoperative dressings). More recently, the term has sometimes been used to describe hydrogel dressings which are fundamentally different to hydrocolloid dressings.
=== Pharmacokinetics === The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time. Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method). Investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.
Sources: en.wikipedia.org
== Method of action == Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.
== L == Lamina A layer of neurons in a neural structure. In the spinal cord and cerebral cortex, laminae are functionally and anatomically distinct. Lateral geniculate nucleus (LGN) A relay center in the thalamus that receives input from the retina and sends visual information to the visual cortex. Lateral inhibition A neural mechanism in which an excited neuron reduces the activity of its neighbors. Enhances contrast in sensory systems such as vision and touch. Lateral sulcus A deep groove in the cerebral cortex that separates the frontal lobe and parietal lobe from the temporal lobe. Learning The acquisition of new knowledge or skills through experience, study, or teaching. In neuroscience, learning is linked to synaptic plasticity and neural circuit changes. Learning A neurobiological process through which experience induces lasting changes in the nervous system, leading to the acquisition or modification of behavior, knowledge, or skills. Lentiform nucleus A structure within the basal ganglia composed of the putamen and globus pallidus, involved in motor control and learning. Lesion Damage or abnormal change in brain tissue, caused by injury, stroke, disease, or surgery. Lesion studies are used to investigate brain function. Levodopa A precursor to dopamine used in the treatment of Parkinson’s disease. It crosses the blood–brain barrier and is converted to dopamine in the brain. Limbic system A group of interconnected brain structures involved in emotion, motivation, memory, and olfaction. Includes the amygdala, hippocampus, and cingulate cortex.
=== Criteria === According to the International Classification of Sleep Disorders, there are 4 types of criteria. The first one concerns sleep – excessive sleepiness, non-restorative sleep, fatigue, or insomnia. The second and third criteria are about respiration – waking with breath holding, gasping, or choking; snoring, breathing interruptions, or both during sleep. The last criterion revolved around medical issues such as hypertension, coronary artery disease, stroke, heart failure, atrial fibrillation, type 2 diabetes mellitus, mood disorder, or cognitive impairment. Two levels of severity are distinguished: the first is diagnosed by polysomnography or a home sleep apnea test demonstrating five or more predominantly obstructive respiratory events per hour of sleep; 15 or more events diagnose the higher level of severity. If the events occur fewer than 5 times per hour, no obstructive sleep apnea is diagnosed. A considerable night-to-night variability further complicates the diagnosis of OSA. In unclear cases, multiple testing might be required to achieve an accurate diagnosis.
=== Blood supply === The rectus abdominis has many sources of arterial blood supply. Classification of the vascular anatomy of muscles: First, the inferior epigastric artery and vein (or veins) run superiorly on the posterior surface of the rectus abdominis, enter the rectus fascia at the arcuate line, and serve the lower part of the muscle. Second, the superior epigastric artery, a terminal branch of the internal thoracic artery, supplies blood to the upper portion. Finally, numerous small segmental contributions come from the lower six intercostal arteries as well.
== Structure == The territorial matrix is composed of collagen fibrils and proteoglycans, forming a dense matrix around groups of chondrocytes, distinguishing itself from neighboring zones. It is located between the pericellular and interterritorial matrix. The territorial matrix is smaller in size (5-10 μm) than the interterritorial matrix, but larger than the pericellular matrix., The collagen that exists in this region is primarily type II collagen, with some types IX and XI. It is arranged in a finer, more interwoven network than in the interterritorial matrix. Proteoglycans like aggrecan and decorin provide resistance to compressive loads. Several glycoproteins are also present and play roles in the matrix assembly and stabilization. The close packing of the fibrils make the region denser, forming a mechanical barrier around chondrocytes.
Sources: en.wikipedia.org
Biological carbon fixation, or carbon assimilation, is the process by which living organisms convert inorganic carbon (particularly carbon dioxide, CO2) to organic compounds. These organic compounds are then used to store energy and as structures for other biomolecules. Carbon is primarily fixed through photosynthesis, but some organisms use chemosynthesis in the absence of sunlight. Chemosynthesis is carbon fixation driven by chemical energy rather than from sunlight. The process of biological carbon fixation plays a crucial role in the global carbon cycle, as it serves as the primary mechanism for removing CO2 from the atmosphere and incorporating it into living biomass. The primary production of organic compounds allows carbon to enter the biosphere. Carbon is considered essential for life as a base element for building organic compounds. The flow of carbon from the Earth's atmosphere, oceans and lithosphere into lifeforms and then back into the air, water and soil is one of the key biogeochemical cycles (or nutrient cycles). Understanding biological carbon fixation is essential for comprehending ecosystem dynamics, climate regulation, and the sustainability of life on Earth. Organisms that grow by fixing carbon, such as most plants and algae, are called autotrophs. These include photoautotrophs (which use sunlight) and lithoautotrophs (which use inorganic oxidation). Heterotrophs, such as animals and fungi, are not capable of carbon fixation but are able to grow by consuming the carbon fixed by autotrophs or other heterotrophs.
== Function == Elaunin fibers in the periodontal ligament (PDL) have connective tissue that anchors each tooth to the surrounding bone and helps cushion the forces generated while chewing. In studies on rat molars, researchers found that elaunin fibers appear alongside oxytalan and mature elastic fibers. It forms a flexible network that allows the PDL to stretch during function and then return to its original shape.
== Antisense RNA == Antisense RNA is the non-coding and single-stranded RNA that is complementary to a coding sequence of mRNA. It inhibits the ability of mRNA to be translated into proteins. Short antisense RNA transcripts are produced within the nucleus by the action of the enzyme Dicer, which cleaves double-stranded RNA precursors into 21–26 nucleotide long RNA species. There is an antisense-based discovery strategy, rationale and design of screening assays, and the application of such assays for screening of natural product extracts and the discovery of fatty acid condensing enzyme inhibitors. Antisense RNA is used for treating cancer and inhibition of metastasis and vectors for antisense sequestration. Particularly MicroRNAs(miRs) 15 and 16 to a patient in need of the treatment for diagnosis and prophylaxis of cancer. Antisense drugs are based on the fact that antisense RNA hybridizes with and inactivates mRNA. These drugs are short sequences of RNA that attach to mRNA and stop a particular gene from producing the protein for which it encodes. Antisense drugs are being developed to treat lung cancer, diabetes and diseases such as arthritis and asthma with a major inflammatory component. It shows that the decreased expression of MLLT4 antisense RNA 1 (MLLT4‑AS1) is a potential biomarker and a predictor of a poor prognosis for gastric cancer. So far, applications of antisense RNAs in antivirus and anticancer treatments and in regulating the expression of related genes in plants and microorganisms have been explored.
== Related legacy/cover bands featuring former King Crimson members == Since the early 2000s, several bands containing former, recent or current King Crimson members have toured and recorded, performing King Crimson music. Active between 2002 and 2005, the 21st Century Schizoid Band reunited several former King Crimson members who had played on the band's first four albums. The band featured Ian McDonald, Mel Collins, Peter Giles and Michael Giles (the latter subsequently replaced by Ian Wallace), and was fronted by Jakko Jakszyk, a decade prior to his own recruitment into King Crimson. The band engaged in several tours, played material from King Crimson's '60s and '70s catalogue, and recorded several live albums. The band disbanded upon Wallace's death in 2007. Since 2007, Tony Levin has led the trio Stick Men, which also features Pat Mastelotto. The band was initially completed by Chapman Stick player Michael Bernier, replaced in 2010 by touch guitarist and former Fripp student Markus Reuter. This band includes (and reinterprets) King Crimson compositions in their live sets. Reuter and Mastelotto also play together as a duo (previously called "Tuner"), within which they have been known to rework the mid-1980s King Crimson instrumental "Industry" live. Starting in 2023, Reuter, Mastelotto and Trey Gunn revived the moniker "Tuner" (re-styled as "Tu-ner") to perform music from the Double Duo era of King Crimson, plus material from each of their respective solo and combined careers.
=== Impacts of gender stereotypes in health and medicine === Gender stereotypes influence both diagnosis and treatment practices for men and women. Ancient theories, such as those of Hippocrates, perpetuated hierarchical models in which the female body was considered a deviation from the male norm—a view that persisted into the 19th century. Some diseases are underdiagnosed in one sex due to stereotypical associations. For instance, women are less frequently and less accurately diagnosed with myocardial infarction, despite an increase in incidence among women between 2008 and 2013 (+20%). Symptoms in women may differ from those in men and are less well-known or recognized. In 2015, cardiovascular disease accounted for 51% of deaths in women in Europe. Similar disparities exist in other conditions. Women with chronic obstructive pulmonary disease (COPD) are diagnosed later than men, even though prevalence is now similar. Women with autism spectrum disorders are often diagnosed late, which has been linked to significantly reduced life expectancy compared to non-autistic women. Strokes, more common among women, also have more severe outcomes in women but were less studied in female patients as of 2017. Conversely, some conditions such as osteoporosis are underdiagnosed in men, as the disease is often seen as predominantly affecting women. Despite this, men represent one-third of hip fractures and have a higher risk of complications.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.